Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study
TH Open · 13.05.2026 · 10 (CP)
DOI: 10.1055/a-2868-3290 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 13.05.2026. Verfasst von Michal Witkowski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Outpatient Clinic, Copernicus Memorial Hospital, Lodz, lodzkie, Poland. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by platelet counts < 100 ×109/L and variable risk of bleeding. Many adults develop chronic disease requiring second-line therapy. Avatrombopag, an oral thrombopoietin receptor agonist (TPO-RA), has demonstrated high efficacy and favorable safety in clinical trials, but real-world data from Poland are lacking.
Objective
To evaluate the real-world efficacy, durability, treatment-free remission (TFR), and safety of avatrombopag in Polish adults with primary ITP, and to explore predictors of treatment response.
Methods
We conducted a retrospective multicenter study including adults with primary ITP treated with avatrombopag across eight hematology centers in Poland. Responses were defined according to International Working Group criteria and assessed at 1, 3, 6, and 12 months. Univariable logistic regression was used to identify baseline predictors of achieving a platelet response.
Results
A total of 142 patients (median age, 54 years) were included. The cohort was heavily pretreated (median of three prior lines of therapy), with 36.6% previously exposed to another TPO-RA. The median baseline platelet count was 21.5 ×109/L. By month 1, 78.3% of patients achieved a platelet response, including 47.8% who achieved a complete response (CR), with a median time to first documented response of 30 days (corresponding to the first scheduled assessment). Among evaluable patients, response rates (CR + R) remained high at 3, 6, and 12 months (84.1, 90.8, and 96.8%, respectively). Four patients (2.8%) achieved TFR with stable platelet counts after discontinuation. Higher baseline hemoglobin levels and lower bleeding scores were associated with achieving a response. Avatrombopag was well tolerated, with infrequent adverse events, one event of hepatotoxicity, and rare thrombotic events.
Conclusion
Avatrombopag induced rapid, sustained, and well-tolerated platelet responses in a heavily pretreated real-world Polish cohort. These findings support its use as an effective second-line therapy and highlight the potential for treatment de-escalation, including TFR, in selected patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Outpatient Clinic, Copernicus Memorial Hospital, Lodz, lodzkie, Poland.
- Department of Science and Technology, Foundation for Leukemia Patients, Lodz, Poland.
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Masovian Voivodeship, Poland.
- Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Lublin Voivodeship, Poland.
- Hematology Clinic, University Clinical Hospital in Bialystok, Bialystok, Podlaskie Voivodeship, Poland.
- Department of Hematology, Rydygier Provincial Polyclinical Hospital, Torun, Poland.
ORCID-Profile: Michal Witkowski
Zitieren
APA
Witkowski, M., Rytel, J., Kozinska, J., Oleksiuk, J., Piszczek, W., Wiater, E., Kwiatkowski, J., Halka, J., Bogucki, R., Ryzewska, W., & Robak, T. (2026). Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study. TH Open, 10(CP). https://doi.org/10.1055/a-2868-3290
Vancouver
Witkowski M, Rytel J, Kozinska J, Oleksiuk J, Piszczek W, Wiater E, et al. Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study. TH Open. 2026;10(CP). doi:10.1055/a-2868-3290
BibTeX
@article{Witkowski2026,
author = {Witkowski, Michal and Rytel, Jagoda and Kozinska, Justyna and Oleksiuk, Jolanta and Piszczek, Weronika and Wiater, Elzbieta and Kwiatkowski, Jacek and Halka, Janusz and Bogucki, Radoslaw and Ryzewska, Wiktoria and Robak, Tadeusz},
title = {Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study},
journal = {TH Open},
year = {2026},
volume = {10},
number = {CP},
doi = {10.1055/a-2868-3290}
}
EUVIMED